Companies: 10,795·Total market cap: $144.5T

Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares

NNNNNASDAQHealthcare● Active

$17.22

$-5.77(-25.10%)

Market Cap$755806464

P/E Ratio—

52W High$55.65

52W Low$8.3

Avg Volume28K

Open$22.68

Beta4.34

Foreign Private Issuer · Files 20-F / 6-K

Anbio Biotechnology Class A Ordinary Shares (NNNN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001982708 · NNNN · NASDAQ · as of Jun 9, 2026

Filing snapshot

40

Total Filings

6-K

Latest Form

2026-05-19

Most Recent

2025

Filing Since

Financials Earnings View All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001982708 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY

Filed Date

2026-04-07

Fiscal Year End

Apr 7, 2026

Accession No.

0001185185-26-001294

Primary Document

anbio20f123125.htm

View on SEC EDGAR Download PDF Filing Index

Source: data.sec.gov · CIK 0001982708 · Accession 0001185185-26-001294

Latest Key Filings

6-KQuarterly Report

FORM 6-K

2026-05-19

View 6-K on SEC

8-KCurrent Report

No recent filings

Form 4Insider Activity

Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144

Filed Date

Form Type

Description

View

2026-05-19

6-K

Current Report (Foreign Issuer)

FORM 6-K

0001185185-26-001897

6-KCurrent Report (Foreign Issuer)

FORM 6-K

2026-05-19

2026-04-27

6-K

Current Report (Foreign Issuer)

FORM 6-K

0001185185-26-001504

6-KCurrent Report (Foreign Issuer)

FORM 6-K

2026-04-27

2026-04-09

20-F/A

20-F/A

FORM 20-F/A1

0001185185-26-001313

20-F/A20-F/A

FORM 20-F/A1

2026-04-09

2026-04-08

3

Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

0001185185-26-001311

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-08

2026-04-08

3

Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

0001185185-26-001310

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-08

2026-04-08

3

Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

0001185185-26-001308

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-08

2026-04-08

3

Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

0001185185-26-001307

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-08

2026-04-08

3

Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

0001185185-26-001306

3Initial Statement of Beneficial Ownership

Initial Statement of Beneficial Ownership

2026-04-08

2026-04-07

20-F

Annual Report (Foreign Issuer)

FORM 20-F

0001185185-26-001294

20-FAnnual Report (Foreign Issuer)

FORM 20-F

2026-04-07

2026-02-17

6-K

Current Report (Foreign Issuer)

FORM 6-K

0001185185-26-000588

6-KCurrent Report (Foreign Issuer)

FORM 6-K

2026-02-17

2026-01-26

6-K

Current Report (Foreign Issuer)

FORM 6-K

0001185185-26-000269

6-KCurrent Report (Foreign Issuer)

FORM 6-K

2026-01-26

2025-12-30

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-25-126654

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2025-12-30

2025-11-13

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-25-109447

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2025-11-13

2025-04-28

20-F

Annual Report (Foreign Issuer)

ANNUAL REPORT

0001213900-25-035802

20-FAnnual Report (Foreign Issuer)

ANNUAL REPORT

2025-04-28

2025-02-21

6-K

Current Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

0001213900-25-016129

6-KCurrent Report (Foreign Issuer)

REPORT OF FOREIGN PRIVATE ISSUER

2025-02-21

Showing 1–15 of 40 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov) | Updated: Hourly | CIK: 0001982708 | Exchange: NASDAQ · Healthcare

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) has submitted 40 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001982708, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Anbio Biotechnology Class A Ordinary Shares's most comprehensive regulatory disclosure. The most recent Anbio Biotechnology Class A Ordinary Shares 10-K was filed on 2026-04-07 for fiscal year ending 2026. Historical NNNN 10-K annual reports are available from 2023 through 2026.

Investors researching Anbio Biotechnology Class A Ordinary Shares SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Related Companies SEC Filings — Healthcare

KALV SEC Filings →AVNS SEC Filings →CMPS SEC Filings →TALK SEC Filings →RIGL SEC Filings →ANGO SEC Filings →CLPT SEC Filings →CYH SEC Filings →

→ NNNN Financials → NNNN Earnings → NNNN Insider Trades

Frequently Asked Questions

NNNN SEC Filings · 8 questions

Anbio Biotechnology Class A Ordinary Shares (NNNN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 40 filings and access original documents at no cost. Anbio Biotechnology Class A Ordinary Shares's CIK is 0001982708.

NNNN SEC filingsAnbio Biotechnology Class A Ordinary Shares SEC documentsfind NNNN 10-K